Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 12/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.61 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | CHRNG | P07510 | 1/20 | 0.61 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.61 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.61 |
| ▸ | CHRND | Q07001 | 1/20 | 0.61 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015289 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL137144 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL29710884 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL14003841 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL5959022 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL225687 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL29363551 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30930845 | 0.74 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21045978 | 0.74 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Varenicline SCHEMBL20553851 | 0.74 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2581375-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | Medichem, S.A. (ES) | 2013-04-17 | — | — | EP | disclosed |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | MEDICHEM, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| WO-2011154586-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | MEDICHEM, S. A. (ES) | 2011-12-15 | — | — | WO | disclosed |
| EP-1383733-B1 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1589148-A | 5,8, 14-triazatetracyclo [10.3.1.0.2,10.04,8) Succinate salt of hexadeca-2 (11),3,5,7, 9-pentaene and pharmaceutical composition thereof | PFIZER PROD INC (US) | 2005-03-02 | — | — | CN | disclosed |
| WO-2003045394-A1 | SUCCINIC ACID SALTS OF 5,8,14-TRIAZATETRACYCLO'10.3.1.0<2,11>.0<4,9>-HEXADECA-2(11),3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | CYP3A7, CYP3A5, COMT | CHRNB2 233/4885CHRNA4 84/4885CHRNB4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.